Abstract
Background Viet Nam, a high-burden tuberculosis (TB) country, observed marked declines in TB notifications during the COVID-19 pandemic. We sought to determine whether and how COVID-19-related factors have influenced TB transmission and control, as well as their long-term effects, aiming to inform and enhance TB control strategies. Methods We developed a compartmental TB transmission model to estimate COVID-19's impact on TB detection and transmission in Vietnam. We simulated future scenarios to evaluate the potential benefits of enhanced TB case detection. Results The COVID-19 pandemic significantly impacted TB control in Viet Nam, leading to a sharp decline in case detection in 2021. This resulted in approximately 1,900 new TB episodes (95% credible interval [CrI]: 200 - 5,100) and 1,100 TB-related deaths (95% CrI: 100 - 2,700) in that year. Projections suggest that by 2035, these disruptions could contribute to 22,000 additional TB episodes (95% CrI: 1,900 - 63,000) and 5,900 more deaths (95% CrI: 600 - 16,600). We predicted two hypothetical scenarios of enhancing TB case detection. Under the ambitious scenario, enhancing TB case detection could mitigate these potential impacts by preventing 17.8% of new TB episodes (95%CrI: 13.1% - 21.9%) and 34.2% (95%CrI: 31.5% - 37.0%) of TB-related deaths by 2035, compared to no enhancement. Conclusions COVID-19 disruptions have created a backlog of undiagnosed TB cases, increasing transmission and mortality. Sustained investment in diagnostics, healthcare resilience, and proactive policies is essential to mitigate long-term consequences.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Viet Long Bui is a recipient of a postgraduate scholarship from Monash University. James M. Trauer is the recipient of a Discovery Early Career Fellowship from the Australian Research Council (DE230100730). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos